Navigation Links
University of South Florida and Draper team to create advanced devices for testing malaria drugs
Date:2/8/2011

the liver is the first target of the disease. The parasite is carried there after it enters the bloodstream through the bite of an infected mosquito. Once inside the liver, the infecting parasites for most types of malaria multiply and rupture liver cells, escaping back into the bloodstream. (In vivax malaria, some parasites can remain dormant in the liver for extended periods before infecting the blood.) The parasites, now modified to attack red blood cells, rapidly create more parasites, which spread throughout the bloodstream in waves.

Thus, the researchers are concentrating on the liver stage of the malaria life cycle for several reasons:

  • First, at this initial stage of human infection there are fewer parasites -- hundreds or a few thousand in the liver compared to millions once parasites start replicating in the bloodstream. That improves the odds of eliminating the parasite, Dr. Kyle said.

  • Second, vivax has the potential to lay dormant in the liver and re-activate months or years after treatment, causing relapses of malaria. While parasites are in the liver, the person does not feel sick. Once parasites enter the bloodstream, disease symptoms emerge, including chills, fever, headache, body aches, vomiting and exhaustion. If untreated, the deadly falciparum strain can quickly escalate to severe anemia, convulsions, brain damage and coma. "The drugs available to treat the bloodstream stages don't work in the liver," Dr. Adams said. "So if you could get rid of parasites in the liver stage, you could essentially prevent vivax malaria and the transmission of infection."

  • Third, the only drug effective in attacking the liver's reservoir of dormant malaria parasites to help prevent recurrences of vivax malaria is risky for widespread use. Administering Primaquine to people with a red blood cell enzyme deficiency, known as glucose phosphate dehydrogenase (G6PD) deficiency, may trigger severe and potentially le
    '/>"/>

Contact: Anne DeLotto Baier
abaier@health.usf.edu
813-974-3300
University of South Florida (USF Health)
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Boston University School of Medicine researchers receive NIMH brain awards
2. University of Missouri professor elected to American Association for the Advancement of Science
3. University of Illinois study confirms glycerin as a feasible feedstuff for swine
4. University of Maryland shares NSF grant to study urban development impact
5. Columbia University uses technological innovation to study bone structure
6. University of Houston professor named 2010 AAAS Fellow
7. University of Houston researchers helping Pentagon build mind-controlled prosthetics
8. Washington State University researchers honored by top science society
9. Syracuse University team develops functionally graded shape memory polymers
10. Jackson Laboratory and Tufts University announce new Ph.D. track in mammalian genetics
11. University of Illinois research makes plant breeding easier
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
University of South Florida and Draper team to create advanced devices for testing malaria drugs
(Date:7/30/2014)... A team of biologists, led by Clemson University associate ... marine pest that will pave the way for novel ... bio-adhesives for medical and industrial applications. , The team,s ... examined the last larval stage of barnacles that attaches ... natural, possibly polymeric material that acts as an underwater ...
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... and statistically significant improvements in clinical measures of ... the Etiology, Pathogenesis and Treatment of Parkinson's Disease ... positive interim results in patients with Parkinson's disease. ... statistically significant improvement in motor function on the ...
... discovered how a small molecule of RNA called microRNA ?a ... a key protein involved in the early development of heart ... the journal Nature, may aid scientists in their understanding of ... a heart cell, as well as offer researchers a way ...
... Paxinos and Dr Yuri Koutcherov of the Spinal Injuries ... Institute have been awarded ~$200,000 by the Christopher Reeve ... the rat spinal cord over the next two years. ... visit to Australia in 2003 and was impressed with ...
Cached Biology News:Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 2Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 3Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 4Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 5Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 6MicroRNA tweaks protein that controls early heart development 2MicroRNA tweaks protein that controls early heart development 33D Atlas Will Help Navigate The Spinal Cord 2
(Date:7/30/2014)...  Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... of Outstanding Issues (LOI) from the European Medicines Agency,s ... the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained ... candidate being evaluated for weight loss. The ... were adequately addressed by the Company based in part ...
(Date:7/30/2014)... PARK, Md. , July 30, 2014 /PRNewswire-USNewswire/ ... biological components to interrogate biology, but such devices ... biology. As such, researchers have ... for in vitro metabolic engineering to ... on a chip. New devices are envisioned to ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
(Date:7/30/2014)... NCERC at Southern Illinois University Edwardsville ... on corn stover pretreatment methods at a U.S. ... D.C. , “Arun’s selection for presentation at ... to the success of our postdoctoral fellowship program,” ... foresight and vision of SIUE and the Illinois ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Calif., March 30 TorreyPines Therapeutics, Inc. (Nasdaq: ... District Court of the Southern District of New York ... of Axonyx Inc. ("Axonyx") against Axonyx and several of ... in 2006. The plaintiffs alleged that the defendants made ...
... March 30 BioMedical Enterprises, Inc. (BME), a rapidly ... of orthopaedic memory metal implants, announced today that it ... Sales and Marketing. BME specializes in nitinol implants ... ends together to promote bone union. The ...
... Stem Cell Trial to Show Dose-related Significant Improvement in ... Amorcyte, Inc. (Amorcyte) today announced data from its ... product for the treatment of damaged heart muscle following ... between cell dose and biologic effect. This is the ...
Cached Biology Technology:Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed 2BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 3Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 4
GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
Full service including gene cloning, protien expression and purification of 1 liter culture....
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
Protein 3D structure prediction, via threading. Easy to use....
Biology Products: